Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Annals of Thoracic Surgery|May 20, 2022
Clinical Features of Patients With Second Primary Lung Cancer After Head and Neck CancerFumiaki Takatsu, Ken Suzawa, Mikio Okazaki, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|February 8, 2023
Surgical outcome of ipsilateral anatomical resection for lung cancer after pulmonary lobectomyMikio Okazaki, Ken Suzawa, Kazuhiko Shien, et al.
Plos One|May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, et al.
International Journal of Surgery (London, England)|October 14, 2025
Total thymectomy is oncologically superior to partial thymectomy in patients with thymic carcinoma: insights from a multicenter real-world data analysisTatsuya Hayashi, Mikio Okazaki, Toshiharu Mitsuhashi, et al.
The Annals of Thoracic Surgery|March 22, 2025
Comparable Clinical Outcomes Between Segmentectomy and Lobectomy for NSCLC With Unsuspected N1/N2: A Multicenter Real-World Data StudyTsuyoshi Ryuko, Mikio Okazaki, Toshiharu Mitsuhashi, et al.
Cancer Science|October 24, 2021
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapyToshiaki Takahashi, Kazuko Sakai, Hirotsugu Kenmotsu, et al.
Molecular and Clinical Oncology|July 22, 2025
Association of the expression of 5-FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S-1 adjuvant chemotherapy: Follow-up results of the Setouchi Lung Cancer Group Study 1201Junichi Soh, Hiromasa Yamamoto, Norihito Okumura, et al.
Molecular Oncology|October 21, 2023
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT studySatoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, et al.
Pageof 5